JP2023538284A5 - - Google Patents

Info

Publication number
JP2023538284A5
JP2023538284A5 JP2023507996A JP2023507996A JP2023538284A5 JP 2023538284 A5 JP2023538284 A5 JP 2023538284A5 JP 2023507996 A JP2023507996 A JP 2023507996A JP 2023507996 A JP2023507996 A JP 2023507996A JP 2023538284 A5 JP2023538284 A5 JP 2023538284A5
Authority
JP
Japan
Prior art keywords
optionally
nucleotide
rnai oligonucleotide
sense strand
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044541 external-priority patent/WO2022031847A2/en
Publication of JP2023538284A publication Critical patent/JP2023538284A/ja
Publication of JP2023538284A5 publication Critical patent/JP2023538284A5/ja
Pending legal-status Critical Current

Links

JP2023507996A 2020-08-04 2021-08-04 Plp1発現を阻害するための組成物及び方法 Pending JP2023538284A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063061040P 2020-08-04 2020-08-04
US63/061,040 2020-08-04
US202163151445P 2021-02-19 2021-02-19
US63/151,445 2021-02-19
PCT/US2021/044541 WO2022031847A2 (en) 2020-08-04 2021-08-04 Compositions and methods for inhibiting plp1 expression

Publications (2)

Publication Number Publication Date
JP2023538284A JP2023538284A (ja) 2023-09-07
JP2023538284A5 true JP2023538284A5 (cg-RX-API-DMAC7.html) 2024-09-20

Family

ID=77519814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507996A Pending JP2023538284A (ja) 2020-08-04 2021-08-04 Plp1発現を阻害するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240084309A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192478A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023538284A (cg-RX-API-DMAC7.html)
KR (1) KR20230058412A (cg-RX-API-DMAC7.html)
AU (1) AU2021321430A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190481A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000371A1 (cg-RX-API-DMAC7.html)
IL (1) IL300286A (cg-RX-API-DMAC7.html)
MX (1) MX2023001450A (cg-RX-API-DMAC7.html)
TW (1) TW202221121A (cg-RX-API-DMAC7.html)
WO (1) WO2022031847A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202216996A (zh) 2020-06-29 2022-05-01 美商Ionis製藥公司 調節plp1之化合物及方法
WO2023183876A2 (en) * 2022-03-24 2023-09-28 Ionis Pharmaceuticals, Inc. Rnai agents of modulating plp1
CA3247389A1 (en) * 2022-05-12 2023-11-16 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MAPT
JP2025518507A (ja) * 2022-05-13 2025-06-17 ディセルナ ファーマシューティカルズ インコーポレイテッド Sncaの発現を阻害するための組成物及び方法
US20260049309A1 (en) * 2022-08-15 2026-02-19 Novo Nordisk A/S Regulation of activity of rnai molecules
TW202430191A (zh) * 2022-10-11 2024-08-01 德商百靈佳殷格翰國際股份有限公司 用於治療伴有晚期纖維化及/或硬化之nash的方法
TW202430192A (zh) * 2022-10-11 2024-08-01 德商百靈佳殷格翰國際股份有限公司 用於治療nash之劑量方案
AU2023372543A1 (en) * 2022-11-02 2025-04-17 Sanegene Bio Usa Inc. Nucleotide-based enhancement agent for rna delivery and therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
EP1253199A1 (en) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Abasic moieties containing enzymatic nucleic acids
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2008020435A2 (en) * 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
US20110081362A1 (en) * 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
WO2010033225A2 (en) * 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
EP4276187A3 (en) * 2016-12-08 2024-01-17 Case Western Reserve University Methods and compositions for enhancing functional myelin production
TW201945009A (zh) * 2018-02-07 2019-12-01 國立研究開發法人國立精神 神經醫療研究中心 寡樹突細胞專一性啟動子、對PLP1基因具專一性之miRNA、包含該啟動子及/或該miRNA之載體與包含該載體之醫藥組合物
JP7535047B2 (ja) * 2018-12-12 2024-08-15 ディセルナ ファーマシューティカルズ インコーポレイテッド トリループを含む二本鎖核酸インヒビター分子

Similar Documents

Publication Publication Date Title
JP2023536974A5 (cg-RX-API-DMAC7.html)
JP2023103244A5 (cg-RX-API-DMAC7.html)
JP2023518409A5 (cg-RX-API-DMAC7.html)
JP2024081668A5 (cg-RX-API-DMAC7.html)
TWI836693B (zh) 抑制lpa之基因表現之組合物及方法
JP2021521796A5 (cg-RX-API-DMAC7.html)
JP2021518125A5 (cg-RX-API-DMAC7.html)
JP2022553348A5 (cg-RX-API-DMAC7.html)
JP2020529197A5 (cg-RX-API-DMAC7.html)
CN113748208A (zh) 用于抑制中枢神经系统中的基因表达的组合物和方法
JP2023530461A5 (cg-RX-API-DMAC7.html)
JP2021533804A5 (cg-RX-API-DMAC7.html)
US20160076037A1 (en) Modified tgf-beta oligonucleotides
JP2023539341A (ja) Dux4阻害剤およびその使用方法
JP2016506240A5 (cg-RX-API-DMAC7.html)
JP2021511042A5 (cg-RX-API-DMAC7.html)
JP2021520207A5 (cg-RX-API-DMAC7.html)
HRP20220908T1 (hr) MODIFICIRANA RNAi SREDSTVA
JP2024508896A5 (cg-RX-API-DMAC7.html)
JP2017516461A (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
TW202345867A (zh) 抑制運鐵蛋白受體2表現的siRNA
JP2023539341A5 (cg-RX-API-DMAC7.html)
JP2024514880A5 (cg-RX-API-DMAC7.html)
IL295086A (en) Compositions and methods for inhibiting expression of hmgb1
JP2021520355A5 (cg-RX-API-DMAC7.html)